Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:45 am
Author: Getaka|Social: XLinkedIn

Suven Life Sciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹132.35Fairly Valued by 9.97%vs CMP ₹147.00

P/E (15.0) × ROE (87.2%) × BV (₹12.40) × DY (2.00%)

Defaults: P/E=15

₹46.17Overvalued by 68.59%vs CMP ₹147.00
MoS: -218.4% (Negative)Confidence: 53/100 (Moderate)Models: All 3: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹88.0849%Over (-40.1%)
Net Asset ValueAssets₹10.6629%Over (-92.7%)
Revenue MultipleRevenue₹0.4022%Over (-99.7%)
Consensus (3 models)₹46.17100%Overvalued
Key Drivers: EPS CAGR -33.4% drags value — could be higher if earnings stabilize. | Wide model spread (₹0–₹88) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -33.4% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

56
Suven Life Sciences Ltd scores 56/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health68/100 · Strong
ROCE 87.0% ExcellentROE 87.2% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent
Smart Money85/100 · Strong
FII holding up 0.24% (6mo) Slight increaseDII holding up 4.59% MF buyingPromoter increased by 2.79% Positive
Earnings Quality50/100 · Moderate
OPM contracting (-981% → -1,791%) DecliningWorking capital: -440 days (improving) Efficient
Quarterly Momentum25/100 · Weak
Revenue (4Q): -13% YoY DecliningOPM: -3,678.0% (down 1,243.0% YoY) Margin pressure
Industry Rank65/100 · Strong
ROCE 87.0% vs industry 16.4% Above peersROE 87.2% vs industry 15.2% Above peers3Y sales CAGR: -16% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:45 am

Market Cap 3,888 Cr.
Current Price 147
Intrinsic Value₹46.17
High / Low 303/115
Stock P/E
Book Value 12.4
Dividend Yield0.00 %
ROCE87.0 %
ROE87.2 %
Face Value 1.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Suven Life Sciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Suven Life Sciences Ltd 3,888 Cr. 147 303/115 12.40.00 %87.0 %87.2 % 1.00
Zota Health Care Ltd 3,802 Cr. 1,116 1,740/752 93.50.09 %17.0 %36.0 % 10.0
SMS Pharmaceuticals Ltd 3,678 Cr. 393 434/17542.1 81.20.10 %12.2 %11.0 % 1.00
Aarti Drugs Limited 3,162 Cr. 346 575/31217.0 1470.58 %13.5 %13.0 % 10.0
RPG Life Sciences Ltd 3,105 Cr. 1,878 2,725/1,73129.6 3351.07 %32.8 %25.5 % 8.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Suven Life Sciences Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 3343221321213
Expenses 553432274933325541455381106
Operating Profit -52-32-28-24-46-30-31-52-39-44-51-80-103
OPM % -1,719%-1,208%-737%-768%-1,885%-1,267%-3,024%-2,032%-2,435%-2,981%-2,714%-8,671%-3,678%
Other Income 26613644421143
Interest 0000000000000
Depreciation 2222221121111
Profit before tax -51-28-24-13-42-28-28-50-39-44-52-77-102
Tax % 0%0%0%0%0%-4%0%0%0%0%0%0%0%
Net Profit -51-28-24-13-42-27-28-50-39-44-52-77-102
EPS in Rs -2.34-1.27-1.10-0.58-1.91-1.22-1.29-2.28-1.79-2.01-2.36-3.40-4.48

Last Updated: February 4, 2026, 12:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 1:51 am

MetricMar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 117521499543625286131312141277
Expenses 10536139841442730012893134139140172285
Operating Profit 13159102129198-14-116-80-122-126-128-166-278
OPM % 11%31%20%24%32%-5%-917%-593%-1,032%-929%-1,094%-2,487%-3,928%
Other Income 391921232714851429118
Interest 5566521110000
Depreciation 412182121114447665
Profit before tax 6152981231960-106-77-122-118-106-161-275
Tax % -32%28%26%29%37%15,038%-11%-7%0%0%-1%0%
Net Profit 81097287124-24-94-72-122-118-105-161-275
EPS in Rs 0.485.703.764.576.48-1.25-4.94-3.78-5.59-5.42-4.82-7.37-12.25
Dividend Payout % 35%7%35%15%15%-80%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-33.94%20.83%42.53%-119.35%-291.67%23.40%-69.44%3.28%11.02%-53.33%
Change in YoY Net Profit Growth (%)0.00%54.78%21.70%-161.88%-172.31%315.07%-92.85%72.72%7.74%-64.35%

Suven Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-35%
5 Years:-12%
3 Years:-17%
TTM:-16%
Compounded Profit Growth
10 Years:%
5 Years:-24%
3 Years:-12%
TTM:-58%
Stock Price CAGR
10 Years:32%
5 Years:36%
3 Years:43%
1 Year:40%
Return on Equity
10 Years:-13%
5 Years:-62%
3 Years:-55%
Last Year:-87%

Last Updated: September 5, 2025, 1:41 pm

Balance Sheet

Last Updated: February 1, 2026, 2:00 am

MonthMar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 12131313131313131522222223
Reserves 95547583654755226131958235424888259
Borrowings 5510983713436532100
Other Liabilities 381057478118623316912142556
Total Liabilities 199773751816919303182128108389285135337
Fixed Assets 1101723053063082225213837286058
CWIP 41077102500540001
Investments 2003012792230045467622247
Other Assets 8349443919930858157103223051815332
Total Assets 199773751816919303182128108389285135337

Reserves and Borrowings Chart

Cash Flow

MonthMar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 41436810970-53-135-96-128-116-115-154
Cash from Investing Activity + -16-110-39-311-13014656-22-24894155
Cash from Financing Activity + 6179-68-30-525335146396-1-1
Net Cash Flow -7212-39-23217-1814-5-432-220
Free Cash Flow -1525107928-92-137-102-147-119-113-191
CFO/OP 37%113%93%111%57%262%114%119%104%91%95%93%

Free Cash Flow

MonthMar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-42.0050.0019.0058.00164.00-17.00-122.00-85.00-125.00-128.00-129.00-166.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 111283931363664840224073
Inventory Days 2001651832223290
Days Payable 157897891134
Cash Conversion Cycle 1541051441622313664840224073
Working Capital Days 13949554282237041,084234265101-440
ROCE %8%13%15%24%-4%-54%-58%-118%-53%-36%-87%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters 69.56%69.56%69.56%69.56%70.26%70.26%70.26%70.26%70.26%67.36%67.36%70.15%
FIIs 0.48%0.50%0.54%0.46%0.45%0.33%0.34%0.25%0.58%1.17%1.07%0.82%
DIIs 0.08%0.01%0.01%1.05%1.05%1.05%1.05%0.01%0.03%3.39%3.39%4.62%
Public 29.88%29.92%29.88%28.91%28.21%28.34%28.35%29.47%29.12%28.07%28.18%24.42%
No. of Shareholders 76,29180,95374,00368,95966,11663,97563,53764,60366,15964,92164,38164,037

Shareholding Pattern Chart

No. of Shareholders

Suven Life Sciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 6,081,373 2.77 188.494,889,3582026-03-23 09:32:1124.38%
HDFC Balanced Advantage Fund 4,143,548 0.12 128.433,353,0522026-01-25 13:37:4423.58%
HDFC Flexi Cap Fund 4,000,000 0.12 123.98N/AN/AN/A
Invesco India Contra Fund 3,598,511 0.56 111.543,323,9462025-12-14 11:28:188.26%
DSP ELSS Tax Saver Fund 3,285,254 0.59 101.83N/AN/AN/A
ICICI Prudential Value Fund 3,263,091 0.17 101.142,873,3422026-03-23 09:32:1113.56%
DSP Healthcare Fund 2,972,213 3.04 92.122,967,6002026-02-20 06:22:350.16%
DSP Aggressive Hybrid Fund 2,808,197 0.73 87.04N/AN/AN/A
DSP Large & Mid Cap Fund 2,762,648 0.49 85.63N/AN/AN/A
DSP Flexi Cap Fund 2,453,891 0.63 76.06N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) -7.37-4.82-6.63-9.57-5.67
Diluted EPS (Rs.) -7.37-4.82-6.63-9.57-5.67
Cash EPS (Rs.) -7.10-4.52-5.12-8.09-5.33
Book Value[Excl.RevalReserv]/Share (Rs.) 5.0412.3817.216.618.49
Book Value[Incl.RevalReserv]/Share (Rs.) 5.0412.3817.216.618.49
Revenue From Operations / Share (Rs.) 0.300.530.620.811.06
PBDIT / Share (Rs.) -7.10-4.90-5.39-8.05-5.68
PBIT / Share (Rs.) -7.37-5.20-5.69-8.35-6.02
PBT / Share (Rs.) -7.37-4.86-5.42-8.39-6.09
Net Profit / Share (Rs.) -7.37-4.82-5.42-8.39-5.67
NP After MI And SOA / Share (Rs.) -7.37-4.82-5.42-8.39-5.67
PBDIT Margin (%) -2326.94-914.01-867.37-988.42-536.50
PBIT Margin (%) -2414.41-969.62-915.70-1025.51-568.75
PBT Margin (%) -2415.11-907.20-873.52-1029.98-574.80
Net Profit Margin (%) -2415.11-898.63-873.52-1029.98-535.31
NP After MI And SOA Margin (%) -2415.11-898.63-873.52-1029.98-535.31
Return on Networth / Equity (%) -146.14-38.91-31.51-126.88-66.80
Return on Capital Employeed (%) -143.86-41.77-32.81-121.80-68.13
Return On Assets (%) -118.90-36.88-30.41-112.92-56.18
Total Debt / Equity (X) 0.000.000.000.010.00
Asset Turnover Ratio (%) 0.030.030.020.030.04
Current Ratio (X) 3.2118.9922.618.016.45
Quick Ratio (X) 3.2018.9422.618.016.45
Inventory Turnover Ratio (X) 14.070.000.000.000.00
Interest Coverage Ratio (X) -3323.53-674.71-406.21-220.85-88.68
Interest Coverage Ratio (Post Tax) (X) -3448.46-709.43-428.84-229.14-87.49
Enterprise Value (Cr.) 2435.232010.22872.721343.38849.81
EV / Net Operating Revenue (X) 365.88171.9264.46113.4263.05
EV / EBITDA (X) -15.72-18.81-7.43-11.47-11.75
MarketCap / Net Operating Revenue (X) 371.55185.9478.07113.8566.48
Price / BV (X) 22.488.052.8214.028.30
Price / Net Operating Revenue (X) 371.56185.9778.08113.8566.48
EarningsYield -0.06-0.04-0.11-0.09-0.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Cohance Lifesciences Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24299MH2018PLC422236 and registration number is 422236. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 1093.51 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093Contact not found
Management
NamePosition Held
Mr. Vivek SharmaExecutive Chairman
Dr. V Prasada RajuManaging Director
Mr. Pankaj PatwariNon Executive Director
Ms. Shweta JalanNon Executive Director
Mr. Vinod PadikkalNon Executive Director
Mr. Vinod RaoIndependent Director
Mr. K G AnanthakrishnanIndependent Director
Mr. U B Pravin RaoIndependent Director
Ms. Matangi GowrishankarIndependent Director
Mr. Jai Shankar KrishnanIndependent Director

FAQ

What is the intrinsic value of Suven Life Sciences Ltd and is it undervalued?

As of 16 April 2026, Suven Life Sciences Ltd's intrinsic value is ₹46.17, which is 68.59% lower than the current market price of ₹147.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (87.2 %), book value (₹12.4), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Suven Life Sciences Ltd?

Suven Life Sciences Ltd is trading at ₹147.00 as of 16 April 2026, with a FY2026-2027 high of ₹303 and low of ₹115. The stock is currently near its 52-week low. Market cap stands at ₹3,888 Cr..

How does Suven Life Sciences Ltd's P/E ratio compare to its industry?

Suven Life Sciences Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Suven Life Sciences Ltd financially healthy?

Key indicators for Suven Life Sciences Ltd: ROCE of 87.0 % indicates efficient capital utilization; ROE of 87.2 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Suven Life Sciences Ltd profitable and how is the profit trend?

Suven Life Sciences Ltd reported a net profit of ₹-161 Cr in Mar 2025 on revenue of ₹7 Cr. Compared to ₹-122 Cr in Mar 2022, the net profit shows a mixed trend.

Does Suven Life Sciences Ltd pay dividends?

Suven Life Sciences Ltd has a dividend yield of 0.00 % at the current price of ₹147.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Suven Life Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports